Anupam Rasayan Q1 FY27 Earnings Call Transcript Released
Anupam Rasayan India Limited (ARIL) reported a 36% YoY growth in consolidated total income to INR 668 crore for Q1 FY27. The company commercialized ETFA using flow chemistry and signed an LOI with BASQUEVOLT for a potential USD 300 million deal over 10 years. The acquisition of Bliss GVS Pharma is expected to complete by early September. Jayhawk contributed 20-22% to revenue with 19-20% EBITDA margins.
The announcement includes significant positive financial performance, successful commercialization of a new product using advanced technology (flow chemistry), strategic partnerships with potential for substantial long-term revenue, and progress on key acquisitions that are expected to transform the company's business segments.
The company reported strong year-on-year growth in total income and EBITDA, highlighted successful commercialization of new products using advanced technology, and progressed on strategic acquisitions. The management expressed confidence in future growth and value creation.
Anupam Rasayan India Limited (ARIL) has released the transcript of its earnings call for the first quarter of FY27, which concluded on June 30, 2026. The call, held on August 14, 2026, covered both standalone and consolidated financial results.
During the call, management highlighted a strong start to FY27 with consolidated total income growing by 36% year-on-year. A key milestone was the commercialization of Ethyl Trifluoroacetate (ETFA) using flow chemistry, making Anupam Rasayan the first company globally to achieve this. The company also signed a Letter of Intent with BASQUEVOLT for the potential long-term supply of a specialty chemical product, with a potential value of approximately USD 300 million spread over 10 years, expected to begin commercialization during FY27.
The Jayhawk acquisition is strengthening the global platform, providing a strategic manufacturing base in the U.S. and expanding capabilities in advanced chemistries. The proposed acquisition of Bliss GVS Pharma is progressing, expected to be concluded by the first half of September, and is seen as a transformational step in building a complete pharmaceutical platform. Jayhawk contributed approximately 20-22% to the revenue in Q1 FY27 with EBITDA margins of 19-20%.
Financially, consolidated total income for Q1 FY27 stood at INR 668 crores, a 36% year-on-year growth. Consolidated EBITDA increased by 35% to INR 175 crores, with margins maintained at 26%. Profit after tax (PAT) was INR 51 crores, a 6% year-on-year growth. The company has completed its major capex cycle and does not foresee significant capex requirements for the existing Anupam platform in the near term, with estimated capex for FY27-28 in the range of INR 70-80 crores for repair, maintenance, and repurposing.
The company expects the polymer business to contribute 20-25% on a standalone basis and 30-35% on a consolidated basis. Management guided standalone EBITDA margins to be between 24-26% and consolidated margins between 22-24%. The commercialization of ETFA is expected to cater to a market of approximately USD 0.5 billion, with potential to capture 5-10% initially, and the cost parameters are expected to be better, leading to improved margins.
Regarding the Bliss GVS Pharma acquisition, SEBI approval and the open offer have been completed, with the transaction expected to conclude by the first half of September. Management reiterated the confidence in improving Bliss's asset utilization to 60-70% over the next 2-3 years. The company also expects to see improvement in working capital efficiency over time.
What to do with a filing like this
Anupam Rasayan India Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Anupam Rasayan India Limited. Read the original for the full detail.